Extra Space Storage, Inc. (EXR) Stock Price Today
Aura AI Summary
Key Stats
- $28.29BMarket Cap
- 1,688,808Volume
- Real EstateSector
- $152.8552W High
- $126.6752W Low
- 108 DaysTypical Hold Time
- $42.01BEnterprise Value
- 4.84%Div Yield
- -Trading Activity
Track Extra Space Storage, Inc. (EXR) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Extra Space Storage, Inc. has traded between a low of $126.67 and a high of $152.85, highlighting its annual price range. Buy and sell Extra Space Storage, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Most Recent News
Royal Road Minerals expands high-grade silver-gold-antimony veins in Colombia, with system open at depth and north.
Royal Road Minerals has significantly expanded the known area of high-grade silver-gold-antimony veins at its Margaritas target in Colombia, now covering about 400 by 450 meters and remaining open to the north and at depth. Initial drilling intersect...

China boosts gold reserves by 21 tonnes in September, largest monthly increase in 3 years.
In September, China increased its gold reserves by 21 tonnes, marking the biggest monthly gain in three years and continuing a 23-month streak of purchases. This move came as gold prices fell, with the People's Bank of China now holding 2,196 tonnes ...

Eli Lilly's obesity and diabetes drugs drive $15B revenue with strong growth, supporting a buy rating.
Eli Lilly is rapidly growing its obesity and diabetes treatment portfolio, with its tirzepatide-based drugs Mounjaro and Zepbound generating nearly $15 billion in revenue and showing strong year-over-year growth of 91% and 46%, respectively. This gro...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.